OncoMatch/Clinical Trials/NCT07221500
A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)
Is NCT07221500 recruiting? Yes, currently enrolling (Sep 2026). This Phase 2 trial studies NX-5948 for chronic lymphocytic leukemia (cll).
Treatment: NX-5948 — This is a study for patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have previously received treatment with a BTK inhibitor (covalent and non-covalent) and a BCL-2 inhibitor. The main purpose of this study is to test if NX-5948 (bexobrutideg) works to treat patients with CLL/SLL. Participation could last up to 5 years, and possibly longer, if the disease does not progress.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Chronic Lymphocytic Leukemia
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: covalent BTK inhibitor
Must have received a covalent BTK inhibitor (BTKi)
Must have received: non-covalent BTK inhibitor
Must have received a non-covalent BTK inhibitor (BTKi)
Must have received: BCL-2 inhibitor
Must have received a BCL-2 inhibitor
Cannot have received: BTK degrader
Previously treated with a BTK degrader
Cannot have received: systemic anticancer therapy
Exception: continuation of hormonal therapy for breast and prostate cancer is allowed, if not on the list of prohibited concomitant medications
No other systemic anticancer therapy is allowed at the same time as this study; exception: continuation of hormonal therapy for breast and prostate cancer is allowed, if they are not on the list of prohibited concomitant medications in this study
Lab requirements
Blood counts
Adequate organ and bone marrow function
Kidney function
Adequate organ and bone marrow function
Liver function
Adequate organ and bone marrow function
Adequate organ and bone marrow function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- City of Hope · Duarte, California
- Colorado Blood Institute · Denver, Colorado
- University of Miami · Coral Gables, Florida
- Florida Cancer Specialists · Sarasota, Florida
- Fort Wayne Oncology and Hematology · Fort Wayne, Indiana
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT07221500 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior BTK degrader, systemic anticancer therapy disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages